Fitzpatrick
Pharmaceuticals
Fundacao OsWaldo Cruz
Falkland Islands
Biography
Mark J. Fitzpatrick was named President and Chief Executive Officer in September 2016, having previously served as our Chief Financial Officer since June 2015. Prior to joining Chiasma, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., a biopharmaceutical company specializing in the treatment of rare diseases, from May 2011 to June 2015. From July 2007 to April 2011, Mr. Fitzpatrick served as Chief Financial Officer of Proteon Therapeutics, Inc. (NASDAQ: PRTO), a biopharmaceutical company. He also held the position of Chief Financial Officer at RenaMed Biologics, Inc.,
Research Interest
Lipidology, Vascular biology, Immunology
